David Olmeda

Madrid, MD, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications

Midkine inhibits dormancy of disseminated melanoma cells.

Midkine inhibits dormancy of disseminated melanoma cells.

Journal: bioRxiv : the preprint server for biology
Published: June 12, 2025

Systemic rewiring of dendritic cells by melanoma-secreted midkine impairs immune surveillance and response to immune checkpoint blockade.

Systemic rewiring of dendritic cells by melanoma-secreted midkine impairs immune surveillance and response to immune checkpoint blockade.

Journal: Nature cancer
Published: March 17, 2023

Physiological models for in vivo imaging and targeting the lymphatic system: Nanoparticles and extracellular vesicles.

Physiological models for in vivo imaging and targeting the lymphatic system: Nanoparticles and extracellular vesicles.

Journal: Advanced drug delivery reviews
Published: February 01, 2021

Live imaging of neolymphangiogenesis identifies acute antimetastatic roles of dsRNA mimics.

Live imaging of neolymphangiogenesis identifies acute antimetastatic roles of dsRNA mimics.

Journal: EMBO molecular medicine
Published: June 11, 2020

UNR/CSDE1 Drives a Post-transcriptional Program to Promote Melanoma Invasion and Metastasis.

UNR/CSDE1 Drives a Post-transcriptional Program to Promote Melanoma Invasion and Metastasis.

Journal: Cancer cell
Published: September 19, 2019

Midkine rewires the melanoma microenvironment toward a tolerogenic and immune-resistant state.

Midkine rewires the melanoma microenvironment toward a tolerogenic and immune-resistant state.

Journal: Nature medicine
Published: June 28, 2019

p62/SQSTM1 Fuels Melanoma Progression by Opposing mRNA Decay of a Selective Set of Pro-metastatic Factors.

p62/SQSTM1 Fuels Melanoma Progression by Opposing mRNA Decay of a Selective Set of Pro-metastatic Factors.

Journal: Cancer cell
Published: July 18, 2017

Systems analysis identifies melanoma-enriched pro-oncogenic networks controlled by the RNA binding protein CELF1.

Systems analysis identifies melanoma-enriched pro-oncogenic networks controlled by the RNA binding protein CELF1.

Journal: Nature communications
Published: December 16, 2016

The nuclear corepressor 1 and the thyroid hormone receptor β suppress breast tumor lymphangiogenesis.

The nuclear corepressor 1 and the thyroid hormone receptor β suppress breast tumor lymphangiogenesis.

Journal: Oncotarget
Published: September 01, 2016

Metastatic risk and resistance to BRAF inhibitors in melanoma defined by selective allelic loss of ATG5.

Metastatic risk and resistance to BRAF inhibitors in melanoma defined by selective allelic loss of ATG5.

Journal: Autophagy
Published: July 28, 2016

Erratum to: Vegfr3-CreER T2 mouse, a new genetic tool for targeting the lymphatic system.

Erratum to: Vegfr3-CreER T2 mouse, a new genetic tool for targeting the lymphatic system.

Journal: Angiogenesis
Published: June 09, 2016

Whole-body imaging of lymphovascular niches identifies pre-metastatic roles of midkine.

Whole-body imaging of lymphovascular niches identifies pre-metastatic roles of midkine.

Journal: Nature
Published: March 10, 2016
Showing 1-12 of 19

Last Updated: 09/26/2026